AbbVie Posts More Positive Hep-C Results, ENTA Jumps
Insights - Last month, AbbVie (ABBV) reported that its new Hepatitis-C treatment was effective in 96% of patients who had never been treated for the virus. On … Continue Reading
Read NowInsights
This CNS Drug Developer is Getting Interesting
Insights - -Buy near recent financing price. Stock is attractive into year-end, but more importantly, could be a top biotech play in 2014. Note that stock is relatively … Continue Reading
Premium: Read Now
The Turnaround Begins: Icahn Backs Hologic Board & Management
Insights - In two press releases on Monday morning, Hologic (HOLX) announced the hiring of a new CEO and the addition of two new independent members to … Continue Reading
Premium: Read Now
The Annual Meeting of the American Society of Hematology in Brief
Insights - This week’s Annual Meeting of the American Society of Hematology (ASH) will highlight new treatments, new indications, new pathways and new ways of engineering cancer-treating … Continue Reading
Read NowBiotech Recap: Our Top Stories from the Week
Insights - Last week we introduced a new look for PropThink.com and launched a more affordable option for PropThink readers interested in exploring our Premium content. Not to worry, we’ll still … Continue Reading
Read Now
Data Support New Indications for Theravance and Glaxo in Asthma
Insights - GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) posted positive results from a phase 3 study of its combination drug, Ellipta (FF/VI), as an asthma medication. The … Continue Reading
Read Now
Novartis Myeloma Drug Shows Early Promise in Key Trial
Insights - An experimental drug from Novartis (NVS) designed to treat a bone marrow cancer met its primary goal in a phase 3 study. In an earlier … Continue Reading
Read Now